Treatment patterns and associated costs for genital warts in Italy

Current Medical Research and Opinion

Volumn 24, Issue 11, 2008, Pages 3175-3183

  Merito, M ^a   Largeron, Nathalie ^b   Cohet, C ^b   Timelli, L ^a   Boselli, F ^c   Matteelli, A ^d   Naldi, L ^e   Vittori, G ^f  

^a Informa   (Italy)

^b SANOFI PASTEUR   (France)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e Bergamo General Hospital   (Italy)

^f SAN CARLO DI NANCY HOSPITAL   (Italy)

Author keywords

Cost of treatment; Genital warts; Human papillomavirus; Quadrivalent vaccine; Resource utilisation

Indexed keywords

IMIQUIMOD; PODOPHYLLIN; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG; WARTEC;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FUNDING; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH SERVICE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; ITALY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PRESCRIPTION; RECURRENT DISEASE; RETROSPECTIVE STUDY; WART VIRUS;

ADOLESCENT; ADULT; CONDYLOMATA ACUMINATA; FEMALE; HEALTH CARE COSTS; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; ITALY; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 58249122108     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802485694     Document Type: Article

References (20)

1. Fenton KA, Lowndes CM. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex Transm Infect 2004;80:255-263 (Pubitemid 39070785)
2. A Complex Picture. HIV and other sexually transmitted infections in the United Kingdom: 2006. Health Protection Agency, London: UK Collaborative Group for HIV and STI Surveillance, 2006. Available at: http://www.hpa.org.uk/webw/ HPAweb&HPAwebStandard/HPAweb-C/1196942145471?p=1158945066450 [Last accessed 18 April 2008]
3. Trends in genital warts and genital herpes diagnoses in the United Kingdom. Health Protection Agency. Health Protection Report,Volume 1, Number 35, 31 August 2007. Available at: http://www.hpa.org.uk/webc/HPAwebFile/ HPAweb-C/1203084376408 [Last accessed 18 April 2008]
4. Giuliani M, Suligoi B. L'infezione da HPV e le altre MST in Italia. From: Human Papilloma Virus: Le acquisizioni di base e la ricerca clinica, 2005:7-14
5. Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J 2006;12:5
6. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-603 (Pubitemid 33044469)
7. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527 (Pubitemid 36159887)
8. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397-1403 (Pubitemid 36702873)
9. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998;9:571-578 (Pubitemid 28474812)
10. Lacey CJN, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV- 6/11 disease. Vaccine 2006;24S3:S3/35-S3/41 (Pubitemid 44293033)
11. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician 2004;70:2335-2342 (Pubitemid 39657182)
12. Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008: published online 13 March 2008 (Pubitemid 351871484)
13. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927 (Pubitemid 46740302)
14. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-1943 (Pubitemid 46740303)
15. Monsonégo J, Breugelmans JG, Bouée S, et al. Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France. [Article in French] Gynecol Obstet Fertil 2007;35:107-113
16. van der Meijden WI, Notowicz A, Blog FB, et al. A retrospective analysis of costs and patterns of treatment for external genital warts in the Netherlands. Clin Ther 2002;24:183-196 (Pubitemid 34117533)
17. Langley PC, White DJ, Drake SM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004;15:501-508 (Pubitemid 39120231)
18. Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22: 663-670
19. Vittori G, Matteelli A, Boselli F, et al. A new approach to estimate genital warts incidence and prevalence in the Italian general female population. It J Gynaecol Obstet 2008;20:33-42 (Pubitemid 351802376)
20. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008: doi: 10.1111/j.1471- 0528.2008.01743.x (Pubitemid 351841762)